Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

Yoshihiro Kakeji, Eiji Oki, Akinori Egashira, Noriaki Sadanaga, Ikuo Takahashi, Masaru Morita, Yasunori Emi, Yoshihiko Maehara

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer. Methods: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m2 on days 1 and 15, and oral S-1 80 mg/m 2/day on days 1-14 every 4 weeks. The primary endpoint was objective response. Results: Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40% (95% CI: 24-56%). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23%) and leukocytopenia (15%). Conclusion: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.

Original languageEnglish
Pages (from-to)49-52
Number of pages4
JournalOncology
Volume77
Issue number1
DOIs
Publication statusPublished - Jul 1 2009

Fingerprint

docetaxel
Stomach Neoplasms
Investigational Drugs
Leukopenia
Ambulatory Care Facilities
Neutropenia
Disease-Free Survival
Appointments and Schedules
Therapeutics
Survival
S 1 (combination)

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kakeji, Y., Oki, E., Egashira, A., Sadanaga, N., Takahashi, I., Morita, M., ... Maehara, Y. (2009). Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Oncology, 77(1), 49-52. https://doi.org/10.1159/000226111

Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. / Kakeji, Yoshihiro; Oki, Eiji; Egashira, Akinori; Sadanaga, Noriaki; Takahashi, Ikuo; Morita, Masaru; Emi, Yasunori; Maehara, Yoshihiko.

In: Oncology, Vol. 77, No. 1, 01.07.2009, p. 49-52.

Research output: Contribution to journalArticle

Kakeji, Y, Oki, E, Egashira, A, Sadanaga, N, Takahashi, I, Morita, M, Emi, Y & Maehara, Y 2009, 'Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer', Oncology, vol. 77, no. 1, pp. 49-52. https://doi.org/10.1159/000226111
Kakeji, Yoshihiro ; Oki, Eiji ; Egashira, Akinori ; Sadanaga, Noriaki ; Takahashi, Ikuo ; Morita, Masaru ; Emi, Yasunori ; Maehara, Yoshihiko. / Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. In: Oncology. 2009 ; Vol. 77, No. 1. pp. 49-52.
@article{94a157c6592649b1ab32ca4d7643dcda,
title = "Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer",
abstract = "Objective: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer. Methods: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m2 on days 1 and 15, and oral S-1 80 mg/m 2/day on days 1-14 every 4 weeks. The primary endpoint was objective response. Results: Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40{\%} (95{\%} CI: 24-56{\%}). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23{\%}) and leukocytopenia (15{\%}). Conclusion: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.",
author = "Yoshihiro Kakeji and Eiji Oki and Akinori Egashira and Noriaki Sadanaga and Ikuo Takahashi and Masaru Morita and Yasunori Emi and Yoshihiko Maehara",
year = "2009",
month = "7",
day = "1",
doi = "10.1159/000226111",
language = "English",
volume = "77",
pages = "49--52",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

AU - Kakeji, Yoshihiro

AU - Oki, Eiji

AU - Egashira, Akinori

AU - Sadanaga, Noriaki

AU - Takahashi, Ikuo

AU - Morita, Masaru

AU - Emi, Yasunori

AU - Maehara, Yoshihiko

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Objective: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer. Methods: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m2 on days 1 and 15, and oral S-1 80 mg/m 2/day on days 1-14 every 4 weeks. The primary endpoint was objective response. Results: Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40% (95% CI: 24-56%). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23%) and leukocytopenia (15%). Conclusion: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.

AB - Objective: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer. Methods: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m2 on days 1 and 15, and oral S-1 80 mg/m 2/day on days 1-14 every 4 weeks. The primary endpoint was objective response. Results: Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40% (95% CI: 24-56%). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23%) and leukocytopenia (15%). Conclusion: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.

UR - http://www.scopus.com/inward/record.url?scp=67649159582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649159582&partnerID=8YFLogxK

U2 - 10.1159/000226111

DO - 10.1159/000226111

M3 - Article

C2 - 19556809

AN - SCOPUS:67649159582

VL - 77

SP - 49

EP - 52

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -